CYLD dysregulation in pathogenesis of sporadic inclusion body myositis.

Satoshi Yamashita, Yoshimasa Matsuo, Nozomu Tawara, Kentaro Hara, Masanori Yamamoto, Tomo Nishikami, Kensuke Kawakami, Xiao Zhang, Ziwei Zhang, Tsukasa Doki, Yukio Ando
Author Information
  1. Satoshi Yamashita: Department of Neurology, Graduate School of Medical Sciences, Kumamoto University, 1-1-1 Honjo, Chuo-ku, Kumamoto, 860-8556, Japan. y-stsh@kumamoto-u.ac.jp. ORCID
  2. Yoshimasa Matsuo: Department of Neurology, Graduate School of Medical Sciences, Kumamoto University, 1-1-1 Honjo, Chuo-ku, Kumamoto, 860-8556, Japan.
  3. Nozomu Tawara: Department of Neurology, Graduate School of Medical Sciences, Kumamoto University, 1-1-1 Honjo, Chuo-ku, Kumamoto, 860-8556, Japan.
  4. Kentaro Hara: Department of Neurology, Graduate School of Medical Sciences, Kumamoto University, 1-1-1 Honjo, Chuo-ku, Kumamoto, 860-8556, Japan.
  5. Masanori Yamamoto: Department of Neurology, Graduate School of Medical Sciences, Kumamoto University, 1-1-1 Honjo, Chuo-ku, Kumamoto, 860-8556, Japan.
  6. Tomo Nishikami: Department of Neurology, Graduate School of Medical Sciences, Kumamoto University, 1-1-1 Honjo, Chuo-ku, Kumamoto, 860-8556, Japan.
  7. Kensuke Kawakami: Department of Neurology, Graduate School of Medical Sciences, Kumamoto University, 1-1-1 Honjo, Chuo-ku, Kumamoto, 860-8556, Japan.
  8. Xiao Zhang: Department of Neurology, Graduate School of Medical Sciences, Kumamoto University, 1-1-1 Honjo, Chuo-ku, Kumamoto, 860-8556, Japan.
  9. Ziwei Zhang: Department of Neurology, Graduate School of Medical Sciences, Kumamoto University, 1-1-1 Honjo, Chuo-ku, Kumamoto, 860-8556, Japan.
  10. Tsukasa Doki: Department of Neurology, Graduate School of Medical Sciences, Kumamoto University, 1-1-1 Honjo, Chuo-ku, Kumamoto, 860-8556, Japan.
  11. Yukio Ando: Department of Neurology, Graduate School of Medical Sciences, Kumamoto University, 1-1-1 Honjo, Chuo-ku, Kumamoto, 860-8556, Japan.

Abstract

Sporadic inclusion body myositis (sIBM) is the most commonly acquired myopathy in middle-aged and elderly people. The muscle histology is characterized by both inflammation and degeneration, including sarcoplasmic aggregation of TDP-43. Cylindromatosis (CYLD) is a deubiquitinating enzyme that targets Lys63-linked ubiquitin chains and negatively regulates signal transduction pathways, such as NF-κB signalling pathways. We examined localization of CYLD as well as phosphorylated TDP-43, phosphorylated p62, and Lys63-linked ubiquitin in muscle tissues of sIBM patients and muscle-specific wild-type TDP-43 transgenic (TDP-43 TG) mice. We investigated whether overexpression of CYLD can affect muscle toxicity in the cell models treated by endoplasmic reticulum (ER) stress inducers tunicamycin and thapsigargin. CYLD expressed with phosphorylated TDP-43, phosphorylated p62, and Lys63-linked ubiquitin in the nuclear and perinuclear regions of muscle fibres of wild-type TDP-43 TG mice and the degenerative myofibres of sIBM patients with rimmed vacuoles and endomysial cellular infiltration. Although expression levels of CYLD decreased and cell viability was reduced in cells treated with ER stress inducers, wild-type CYLD, but not the catalytic mutant, substantially improved cell viability based on the deubiquitinase activity. Dysregulation of CYLD may reinforce myodegeneration in the pathophysiology of sIBM by attenuating autophagic clearance of protein aggregates. Regulating CYLD in muscle fibres might serve as a novel therapeutic strategy for sIBM treatment.

References

  1. Presse Med. 2011 Apr;40(4 Pt 2):e219-35 [PMID: 21392932]
  2. Neuromuscul Disord. 2013 Dec;23(12):1044-55 [PMID: 24268584]
  3. Ann Neurol. 2013 Mar;73(3):397-407 [PMID: 23460448]
  4. Ann Neurol. 2013 Mar;73(3):408-18 [PMID: 23596012]
  5. Curr Drug Targets. 2015;16(4):284-94 [PMID: 25342597]
  6. Acta Neuropathol. 2015 May;129(5):611-24 [PMID: 25579751]
  7. Exp Neurol. 2018 Nov;309:169-180 [PMID: 30130494]
  8. Neuropathol Appl Neurobiol. 2011 Apr;37(3):226-42 [PMID: 21155862]
  9. Muscle Nerve. 2009 Jul;40(1):19-31 [PMID: 19533646]
  10. Exp Neurol. 2007 Apr;204(2):610-8 [PMID: 17261282]
  11. J Neurol. 2012 Mar;259(3):554-6 [PMID: 21800140]
  12. Nat Cell Biol. 2011 Oct 30;13(12):1437-42 [PMID: 22037414]
  13. J Neurochem. 2006 Mar;96(5):1491-9 [PMID: 16441512]
  14. Brain. 2011 Nov;134(Pt 11):3167-75 [PMID: 21908393]
  15. PLoS One. 2011 Mar 07;6(3):e17477 [PMID: 21408173]
  16. Nat Genet. 2000 Jun;25(2):160-5 [PMID: 10835629]
  17. Cell Death Dis. 2017 Jun 29;8(6):e2905 [PMID: 28661482]
  18. Neuromuscul Disord. 2017 Apr;27(4):363-369 [PMID: 28159418]
  19. Brain. 2011 Nov;134(Pt 11):3176-84 [PMID: 21994327]
  20. Neuropathol Appl Neurobiol. 2013 Jun;39(4):406-16 [PMID: 22860700]
  21. Nature. 2003 Aug 14;424(6950):793-6 [PMID: 12917689]
  22. Am J Respir Crit Care Med. 2011 Nov 1;184(9):1030-40 [PMID: 21816939]
  23. Cell. 2008 Dec 26;135(7):1311-23 [PMID: 19109899]
  24. FEBS Lett. 2010 Feb 19;584(4):662-8 [PMID: 20043910]
  25. Neurology. 2000 Jul 25;55(2):296-8 [PMID: 10908910]
  26. Crit Rev Immunol. 2009;29(3):241-54 [PMID: 19538137]
  27. J Neurol Neurosurg Psychiatry. 2008 Oct;79(10):1186-9 [PMID: 18796596]
  28. Am J Pathol. 2004 Jan;164(1):1-7 [PMID: 14695312]
  29. Cell Death Differ. 2010 Jan;17(1):25-34 [PMID: 19373246]
  30. Rheum Dis Clin North Am. 2002 Nov;28(4):779-98, vi [PMID: 12506772]
  31. Neurosci Lett. 1998 Sep 25;254(2):77-80 [PMID: 9779924]
  32. Ann Neurol. 2017 Apr;81(4):512-525 [PMID: 28318044]

MeSH Term

Aged
Animals
Deubiquitinating Enzyme CYLD
Endoplasmic Reticulum Stress
Humans
Mice
Mice, Transgenic
Middle Aged
Myositis, Inclusion Body
Phosphorylation
Proteomics
Ubiquitin
Vacuoles

Chemicals

Ubiquitin
CYLD protein, human
Deubiquitinating Enzyme CYLD

Word Cloud

Created with Highcharts 10.0.0CYLDTDP-43sIBMmusclephosphorylatedLys63-linkedubiquitinwild-typecellinclusionbodymyositispathwaysp62patientsTGmicetreatedERstressinducersfibresviabilitySporadiccommonlyacquiredmyopathymiddle-agedelderlypeoplehistologycharacterizedinflammationdegenerationincludingsarcoplasmicaggregationCylindromatosisdeubiquitinatingenzymetargetschainsnegativelyregulatessignaltransductionNF-κBsignallingexaminedlocalizationwelltissuesmuscle-specifictransgenicinvestigatedwhetheroverexpressioncanaffecttoxicitymodelsendoplasmicreticulumtunicamycinthapsigarginexpressednuclearperinuclearregionsdegenerativemyofibresrimmedvacuolesendomysialcellularinfiltrationAlthoughexpressionlevelsdecreasedreducedcellscatalyticmutantsubstantiallyimprovedbaseddeubiquitinaseactivityDysregulationmayreinforcemyodegenerationpathophysiologyattenuatingautophagicclearanceproteinaggregatesRegulatingmightservenoveltherapeuticstrategytreatmentdysregulationpathogenesissporadic

Similar Articles

Cited By